Metraipolis › archive › dc_6b1344fde079
Efficacy and safety of Chinese patent medicine in the adjuvant treatment of prostate cancer: A Bayesian network meta-analysis — Europe PMC PMID:38517994
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38517994
- DOI
- 10.1097/md.0000000000037180
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T22:03:43.566Z
- SHA-256 of the archived text
7821bda4cc1d228f1f6da25b6848cef75986040c6796e2d340f13ce6e6ff041d- Stable URL of this page
https://metraipolis.com/documento/dc_6b1344fde079
How to cite
Efficacy and safety of Chinese patent medicine in the adjuvant treatment of prostate cancer: A Bayesian network meta-analysis — Europe PMC PMID:38517994 — Europe PMC (en), https://europepmc.org/article/MED/38517994 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6b1344fde079 (Metraipolis archive dc_6b1344fde079, sha256 7821bda4cc1d228f1f6da25b6848cef75986040c6796e2d340f13ce6e6ff041d)
BibTeX
@misc{dc6b1344fde079,
title = {Efficacy and safety of Chinese patent medicine in the adjuvant treatment of prostate cancer: A Bayesian network meta-analysis — Europe PMC PMID:38517994},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38517994},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6b1344fde079; sha256 7821bda4cc1d228f1f6da25b6848cef75986040c6796e2d340f13ce6e6ff041d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38517994. Agents can read the archived copy with the MCP tool read_document.